Ixaltis
Toulouse
About Ixaltis
Ixaltis is a pharmaceutical company that develops therapeutics to treat genitourinary disorders with unsatisfied medical needs. The company was born out of the combined expertise of scientists specialized in urology, pharmaceutical experts and experienced managers: Dr. Philippe Lluel, Christian Chavy, Stefano Palea, Dr. Roberto Gradnik and Professors Pascal Rischmann and Xavier Gamé. The vision of IXALTIS is to develop treatments for genito-urinary tract diseases with still a high unmet medical need, by identifying drugs which had already reached clinical stage and reexplore these for use in genitourinary tract disorders. IXALTIS has established a proprietary position covering Litoxetine for use in urogenital and other disorders based on its specific mechanism of action.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $8.0M
- Last round: Series Unknown (May 2016)
- Website: ixaltis.com
- Phone: +33 (0)4 57 26 00 76
Industries & Categories
Biopharma, Biotechnology, Health Care, Medical, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/ixaltis-78671 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.